Cases & Deals

  • Home
  • Practices
  • Pfizer is involved in joint venture with GlaxoSmithKline to create new world-leading HIV company focused on research, development and commercialization of HIV medicines

Share

Pfizer is involved in joint venture with GlaxoSmithKline to create new world-leading HIV company focused on research, development and commercialization of HIV medicines

April 2009

Client(s) Pfizer, Inc.

Jones Day represented Pfizer, Inc. in its agreement with GlaxoSmithKline plc to create a new world-leading HIV company focused solely on research, development and commercialization of HIV medicines. GlaxoSmith Kline will initially hold an 85% equity interest in the new company and Pfizer will hold 15%. The transaction is expected to close in the fourth quarter of 2009.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.